Cost effectiveness of rapid HIV and syphilis testing algorithms in antenatal care Claire C. Bristow, MSc Fielding School of Public Health University of.

Slides:



Advertisements
Similar presentations
Measuring burden of disease Introduction to DALYs FETP India.
Advertisements

EMTCT Tanzania Experience 6 th Joint Biennial HIV & AIDS Sector Review Dr MD Kajoka PMTCT Coordinator.
Adding It Up: The Costs and Benefits of Investing in Sexual and Reproductive Health 2014 Presented by Susheela Singh Guttmacher Institute December 4, 2014.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) HIV Prevention Training Package Session 1: Introduction.
PMTCT Generic Training Package Module 3 Slide 1 Specific Interventions to Prevent MTCT M O D U L E 3.
Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Foundation J2J Global Media Training on HIV/AIDS July 14, 2010 Vienna, Austria.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Maternal and Newborn Health Training Package Session 11:
Infant Mortality: Annual number of children under 1 year of age who die per 1,000 live births Under 5 Mortality/5 yr Child Survival Life Expectancy at.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Introduction to decision modelling Andrew Sutton.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
1 Intermittent preventive treatment of malaria in pregnancy: incremental Cost-effectiveness of a new delivery system in Uganda. AK Mbonye, KS Hansen, IC.
“Getting to Zero: Thailand’s Experience with E-MTCT” Petchsri Sirinirund Advisor on HIV/AIDS Policy and Programme Department of Disease Control, Thailand.
Schneider Institute for Health Policy Heller Graduate School Brandeis University 1 by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller.
CD4 assessment among newly diagnosed HIV-infected pregnant women in India’s National Prevention of Parent to Child Transmission Programme (PPTCT) Implications.
Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.
Purpose Provide concepts and latest research findings related to prevention of mother-to-child transmission of HIV (PMTCT) for application in the workplace.
A cost-effectiveness evaluation of preventive interventions for HIV-TB in Sub-Saharan Africa (Tanzania): Relevance for neurological infections Lucie Jean-Gilles.
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
1 Potential Impact and Cost-Effectiveness of the 2009 “Rapid Advice” PMTCT Guidelines — 15 Resource-Limited Countries, 2010 Andrew F. Auld, Omotayo Bolu,
1 Econoqualimetrics Edward Broughton, PhD., MPH Senior Economic Analyst, USAID Health Care Improvement Project, EnCompass,
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV WHAT’S NEW Prepared by Dr. Debbie Carrington National HIV/AIDS Prevention & Control Programme Ministry.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Child Health: How Have We Been Doing; Where to Now? An Update on MDG 4 and 5: Maternal and Child Health By Dr. Mickey Chopra, Chief, Health and Associate.
GETTING READY FOR DUAL EMTCT VALIDATION IN THE AMERICAS Adele Schwartz Benzaken.
Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.
Prevention of Mother-to-Child Transmission of HIV infection in Sri Lanka Dr Sujatha Samarakoon Consultant Venereologist / Focal Point ECS & PMTCT – National.
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Treatment Last updated: December 2014.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
PERFOMANCE CHARACTERISTICS AND COST BENEFIT OF THE SD BIOLINE HIV/SYPHILIS DUO TEST KIT IN ZIMBABWE Mtapuri-Zinyowera S, Gumbo P, Munemo E, Ncube G, Machiha.
Welcome Enhanced Perinatal Surveillance (EPS) Meeting.
Washington D.C., USA, July 2012www.aids2012.org IS HIV MOTHER TO CHILD TRANSMISSION AND CONGENITAL SYPHILIS ELIMINATION BY 2015 A REALITY IN THE.
Lives at Risk: Malaria in pregnancy
Presentation advocating for in-country rapid syphilis testing These slides provide a template for how to present the case for rapid syphilis testing and.
New Frontiers in Newborn Health: Stephen Wall, MD SM Senior Research Manager Saving Newborn Lives Save the Children.
Washington D.C., USA, July 2012www.aids2012.org Preventing Mother to Child HIV Transmission through Community Based Approach in Nepal Nafisa Binte.
Is Highly Active Antiretroviral Therapy (HAART) in pregnancy protective against maternal mortality? Results from a large DREAM cohort in Malawi and Mozambique.
Costs of Neurostimulation Can We Afford The Therapy in 2020? Krishna Kumar MBBS MS FRCS(C) Member Ord. of Canada, Saskatchewan Ord. of Merit Clinical Professor.
HIV DISEASE IN PREGNANCY
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Vaccines & Biologicals (V&B) Cost-effectiveness of safe injection policies: Study rationale and proposed methodology Ulla Kou, WHO SIGN meeting in New.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Cost-effectiveness of early infant HIV diagnosis and immediate antiretroviral therapy in HIV- infected children
Measures of the health status of Australians. Sources of health data and statistics in Australia Australian Bureau of Statistics (ABS), Australia’s national.
Estimating the Impact and Needs for Children and PMTCT Making sense: Understanding the numbers: from HIV surveillance to national and global HIV burden.
MATERNAL ANTIRETROVIRAL THERAPY AND INFANT OUTCOMES THROUGHOUT THE FIRST YEAR OF LIFE: results from the DREAM study in Dschang, Cameroon Taafo F, Doro.
Comparing Australia with Developing Countries Morbidity, life expectancy, infant mortality, adult literacy and immunisation rates can be used to compare.
A Cost-Effectiveness Analysis of Maternal Genotyping to Guide Treatment in Postnatal Patients.
Adults living with HIV (15+) (thousands) [5] Children living with HIV (0-14) (thousands) [5] Pregnant.
Global Congenital Syphilis Elimination Mary L. Kamb 1, Nathalie Broutet 2, Jennifer Mark 1, Ken Wind-Anderson 2, and John M. Douglas 1 CDC Division of.
Putting Health Metrics Into Practice: Using the Disability-Adjusted Life Year (DALY) for Strategic Decision Making Kim Longfield Brian Smith Rob Gray Lek.
Loss to follow-up of HIV-infected women after delivery: The Swiss Mother and Child HIV Cohort Study Karoline Aebi-Popp, Roger Kouyos, Barbara Bertisch,
Measures of the health status of Australians
Costs and Expected Benefits of Investment in Cervical Cancer Prevention Nicole G. Campos, PhD.
Working Strategies of Chinese Newborn Healthcare
Maternal infections: syphilis and preterm birth
Obstetric and paediatric HIV surveillance data from the UK and Ireland
World Health Organization
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Global updates on elimination and the concept of pre-elimination Shaffiq Essajee WHO HIV Department IATT Webinar: March 17th 2016.
January 2014 Update Obstetric and paediatric HIV surveillance data from the UK and Ireland.
Antiretroviral therapy coverage in sub-Saharan Africa,
Brian Weir Johns Hopkins University
Different measures of health status of Australians
Introduction to Health Economics (1)
Presentation transcript:

Cost effectiveness of rapid HIV and syphilis testing algorithms in antenatal care Claire C. Bristow, MSc Fielding School of Public Health University of California, Los Angeles Satellite Session Sunday July 20 th, 2014

What is a cost-effectiveness study? Economic analysis that compares relative costs and outcomes – In this case we’re looking rapid point-of-care HIV and syphilis testing algorithms

Why do we do cost-effectiveness studies? The concept of cost effectiveness is applied to resource allocation and management activities – Getting the most “bang for your buck” – Spending the least to gain the most – Using evidence to determine how to prioritize resources: “evidence-based public health”

Goals 1.To measure adverse pregnancy outcomes associated with alternative testing strategies 2.To measure the monetary costs of alternative testing strategies 3.To develop a cost-effectiveness model for policy-makers and implementers to determine the most cost-effective dual elimination strategy

We used Malawi as the base case for this analysis Option B+ start lifelong highly-active antiretroviral therapy at 14 weeks of gestation

5 Testing Algorithms Dual rapid test for HIV and syphilis 1 single rapid test for HIV 1 single rapid test for syphilis HIV rapid test Lab-based TPPA/RPR for syphilis HIV rapid test only No Testing

Simulation Model 100,000 pregnant women in Malawi Followed through decision tree (testing pathway) and treatment, each step governed by probabilities Key inputs from data out of Malawi TreeAge Pro Software (Williamstown MA, USA)

Simulation Model Estimated expected adverse pregnancy outcomes based on each testing strategy – HIV mother-to-child transmission (MTCT) – Newborn syphilis infection – Prematurity/low birth weight – Neonatal death – Stillbirth

Decision Tree – Simulation model A schematic tree-shaped diagram used to show a statistical probability Each branch of the decision tree represents a possible event The tree structure shows how one choice or event leads to the next, and the use of branches indicates that each option is mutually exclusive

Decision tree - No testing No testing Proportion HIV uninfected Proportion of HIV uninfected women who are syphilis uninfected Proportion of these women with adverse pregnancy outcome Proportion of HIV uninfected women who are syphilis infected Proportion of these women with adverse pregnancy outcome Proportion HIV infected Proportion of HIV infected women who are syphilis uninfected Proportion of these women with adverse pregnancy outcome Proportion of HIV infected women who are syphilis infected Proportion of these women with adverse pregnancy outcome

One branch of the HIV rapid test only decision tree HIV rapid test algorithm Proportion of women receiving HIV rapid test HIV infected HIV test positive (test sensitivity) HIV treatment received Syphilis infected Pregnancy outcome Syphilis uninfected Pregnancy outcome HIV treatment LTFU …HIV test negative…HIV uninfected…Not tested…

COST EFFECTIVENESS ANALYSIS

Costs We considered costs of testing incurred by both the health system and the woman (labor costs determined using standard WHO health worker salaries for the region, patient travel costs, and test costs, etc.) We included costs of treatment for both syphilis and HIV infection in the pregnant woman and infant All costs were converted to 2012 US Dollars.

Effectiveness: Disability adjusted life years (DALYs) The disability adjusted life years (DALYs) is a measure of overall disease burden, expressed as the number of years lost due to ill-health, disability or early death DALYs were calculated using disability weights from the Global Burden of Disease study 1 A disability weight is a weight factor that reflects the severity of the disease on a scale from 0 (perfect health) to 1 (equivalent to death) DALYs were adjusted for co-infection 2 1.Lopez et al Owusu-Edusei et al 2014

DALYs The DALY metric is used to provide a single number to capture the health impact caused by a illness A DALY of 1 could represent 1 year of life lost (due to early death), 1.7 years spent with blindness, 5.2 episodes of malaria, etc. Syphilis infection in the infant has a disability weight of per year and is estimated to last for 3 years. So a child born with congenital syphilis would receive a lifetime DALY value of 0.945

Incremental cost effectiveness ratio

Key inputs: epidemiology Cohort 10.6% HIV prevalence among pregnant women 1 – 24.8% of those with AIDS % syphilis prevalence among HIV- uninfected 1 2.2% syphilis prevalence among HIV-infected 1 1. Malawi Government Mwapasa 2006

Key inputs Test accuracy Sensitivity and specificity estimates were determined from literature review of field studies

Key inputs: Health system structure and use Treatment Option B+ for treatment of HIV infection Treatment for maternal syphilis infection with one injection (2.4 MU Benzathine Penicillin)

Key inputs: Costs Screening test costs $0.80 Single HIV rapid test $0.55 Single Syphilis rapid test $2.39 Syphilis laboratory tests (RPR/TPPA) 1 $1.30 Dual Rapid test – SD Duo® Patient costs Treatment costs for syphilis or HIV infection for life of infant Pregnancy outcome costs 1. Owusu-Edusei 2011

RESULTS

Expected adverse pregnancy outcomes per 100,000 pregnancies No testing program17,127 adverse outcomes HIV rapid testing only15,820 adverse outcomes HIV rapid testing and laboratory-based syphilis testing 15,779 adverse outcomes 1 single HIV and 1 single syphilis rapid testing 15,775 adverse outcomes Dual HIV/syphilis testing15,370 adverse outcomes

Summary results from the cohort decision model comparing the expected effects (DALYs) of the pregnancy and costs (2012 U.S. Dollars) for all 5 antenatal HIV and syphilis testing algorithms and a no-testing strategy in the Malawi setting. Total Program and Outcome Costs No testing $20,783,454 Dual HIV/syphilis $21,274,678 HIV test only $21,583,611 Single rapid tests for HIV & syphilis $21,593,145 HIV rapid test & RPR/TPPA for syphilis $21,605,356

Summary results from the cohort decision model comparing the expected effects (DALYs) of the pregnancy and costs (2012 U.S. Dollars) for all 5 antenatal HIV and syphilis testing algorithms and a no-testing strategy in the Malawi setting. Total Program and Outcome Costs DALYs No testing $20,783,454269,400 Dual HIV/syphilis $21,274,678228,829 HIV test only $21,583,611235,716 Single rapid tests for HIV & syphilis $21,593,145235,023 HIV rapid test & RPR/TPPA for syphilis $21,605,356235,094

Summary results from the cohort decision model comparing the expected effects (DALYs) of the pregnancy and costs (2012 U.S. Dollars) for all 5 antenatal HIV and syphilis testing algorithms and a no-testing strategy in the Malawi setting. Total Program and Outcome Costs Cost increase from no testing DALYS No testing $20,783, ,400 Dual HIV/syphilis $21,274,678$491,224228,829 HIV test only $21,583,611$800,158235,716 Single rapid tests for HIV & syphilis $21,593,145$809,692235,023 HIV rapid test & RPR/TPPA for syphilis $21,605,356$821,902235,094

Summary results from the cohort decision model comparing the expected effects (DALYs) of the pregnancy and costs (2012 U.S. Dollars) for all 5 antenatal HIV and syphilis testing algorithms and a no-testing strategy in the Malawi setting. Total Program and outcome Costs Cost increase from no testing DALYS DALYs prevented compared to no testing No testing $20,783, ,400- Dual HIV/syphilis $21,274,678$491,224228,82940,571 HIV test only $21,583,611$800,158235,71633,684 Single rapid tests for HIV & syphilis $21,593,145$809,692235,02334,377 HIV rapid test & RPR/TPPA for syphilis $21,605,356$821,902235,09434,306

Summary results from the cohort decision model comparing the expected effects (DALYs) of the pregnancy and costs (2012 U.S. Dollars) for all 5 antenatal HIV and syphilis testing algorithms and a no-testing strategy in the Malawi setting. Total Program and outcome Costs Cost increase from no testing DALYS DALYs prevented compared to no testing ICER* No testing $20,783, , Dual HIV/syphilis $21,274,678$491,224228,82940, HIV test only $21,583,611$800,158235,71633,684 Strictly dominated Single rapid tests for HIV & syphilis $21,593,145$809,692235,02334,377 Strictly dominated HIV rapid test & RPR/TPPA for syphilis $21,605,356$821,902235,09434,306 Strictly dominated *Incremental cost effectiveness ratio (ICER) is the ratio of the change in costs to incremental benefit of an algorithm.

Conclusions A dual HIV/syphilis testing algorithm in antenatal care would be the most effective means to reduce the number of adverse outcomes of pregnancy The dual point-of-care testing algorithm had lower overall costs and decreased life-time disability when compared to the other testing choices

Limitations Did not include procurement costs for tests or training costs Inputs are based on estimates from a variety of studies, actual measures may change over time This is a purely economic perspective, this doesn’t include the intangible values society places on pregnancy outcomes

Conclusions Integrating the screening of syphilis into antenatal HIV prevention programs through dual rapid point-of-care testing would increase the number of maternal infections detected and have the greatest impact on the prevention of HIV and syphilis related adverse pregnancy outcomes

Next steps, sensitivity analyses

Visit our posters! "Cost-effectiveness of dual HIV and syphilis testing“ - Thursday, 24 July 2014 from 12: :30, Exhibition Hall, Ground Level THPE416 “Field evaluation of a dual rapid diagnostic test for HIV and syphilis in Lima Peru using SD BIOLINE HIV/Syphilis Duo“ - Wednesday, 23 July 2014 from 12: :30, Exhibition Hall, Ground Level WEPE050

Acknowledgements Jeffrey Klausner, UCLA Elysia Larson, Harvard Thomas Gift, CDC Kwame Owusu-Edusei, CDC Lori Newman, WHO Fern Terris-Prestholt, LSHTM Peter Vickerman, Bristol University

THANK YOU Please get in touch if you want more information or have comments. Dualelimination.org